Virginia Mandatory Prescription Monitoring System Check

Virginia’s mandatory prescription-monitoring check rule required doctors to consult the state drug-monitoring system each time they issued a prescription, with the stated aim of preventing doctor-shopping. Introduced in 2017 amid exceptionally high opioid prescribing in two rural Virginia localities, the mandate exemplified a turn toward closer oversight of prescribing—but it was only one strand of a response that also had to address access to treatment.

The 2017 Mandate

The Virginia Board of Medicine ordered doctors to check the drug-monitoring system every time they issued a prescription. The rule was intended to prevent doctor-shopping, a practice in which a patient seeks prescriptions from multiple doctors. It made a system check part of each prescribing decision rather than an occasional precaution. The mandate arrived as new Centers for Disease Control and Prevention figures showed that residents of two rural Virginia towns had received more opioid prescriptions per person than residents anywhere else in the country. Martinsville ranked first and Galax fourth. The figures sharpened the context for the rule, but the evidence does not establish that the mandate was a direct response to those rankings or quantify its effect on prescribing.

Background: Prescribing and Oversight

The book places the rule against a history in which medical practice had increasingly treated pain as a priority. When OxyContin was introduced in 1996, doctors, hospitals, and accreditation bodies were adopting pain as the fifth vital sign; mandatory pain-assessment standards followed in 1999. Purdue Pharma’s promotional materials and planned hospital resources aligned the company with those standards. At the same time, the book notes that subjective pain scales could make treatment easier to standardize without reliably improving patient outcomes, while reliance on them increased opioid prescribing and abuse. That history helps explain the broader policy tension surrounding the mandate: prescribing had expanded amid changing clinical standards and commercial promotion, while public authorities were now adding mechanisms to scrutinize prescriptions. The rule represents a regulatory shift toward checking prescribing activity, not evidence that oversight alone resolved the harms associated with opioid use.

Oversight Alongside Treatment

Virginia’s 2017 response included measures beyond prescription monitoring. State health officials were working to expand medication-assisted treatment while tightening controls on its abuse, and Dr. Hughes Melton helped direct the state’s opioid response. The state also pursued a syringe-exchange initiative. These efforts addressed different parts of the crisis: monitoring sought to curb problematic prescribing, while treatment and harm-reduction measures addressed the needs of people already affected by addiction. The book’s accounts of treatment access show why tighter oversight cannot stand in for care. Tess Henry’s buprenorphine treatment required a $700 initial payment and follow-up visits costing $90 to $100, potentially four times a month; her mother also described waiting lists. In Roanoke, a community services board had added medication-assisted treatment for twenty-one patients only if they first engaged in counseling, while Carilion still had a three-week wait for outpatient treatment. These are not stated consequences of the monitoring rule, but they illuminate the wider system in which it operated: rules governing prescriptions and practical access to treatment were separate, simultaneous challenges.

Significance and Limits

The mandate made prescription monitoring a routine condition of issuing a prescription and marked a more assertive state effort to address opioid prescribing. Its arrival alongside high prescribing figures in Martinsville and Galax gives the rule urgency in the book’s account, while the surrounding expansion of treatment and tighter controls on medication-assisted treatment show that Virginia’s response was not limited to surveillance. The evidence does not provide implementation details beyond the required check, nor does it report whether the rule reduced doctor-shopping, opioid prescribing, or overdose. Its significance is therefore clearest as a policy instrument within a broader shift: after years in which clinical norms and marketing helped normalize liberal opioid use, the state sought greater visibility into prescribing while still confronting the harder question of how to make effective treatment reachable.